Senior Director, Corporate Affairs, Communications and Policy Advocacy, Italy

ppRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s RD pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. /p h3The Opportunity /h3 pThe Senior Director, Corporate Affairs, Communication and Policy Advocacy will lead the development and execution of oncology-focused Corporate Affairs strategies in Italy that support the company’s mission of revolutionizing treatment for patients with RAS-addicted cancers. These Corporate Affairs strategies bring together media relations, corporate public affairs, product communications, corporate reputation management and internal communications. /p h3Key Responsibilities /h3 h3Media Relations /h3 ul liActs as spokesperson in Italy, directing enquiries to internal experts as needed. /li liDrives proactive media content and strategy around trial results, regulatory milestones, and major oncology congresses (ASCO, ESMO). /li liBuilds and maintains trusted relationships with top-tiers in Italy and trade media, ensuring accurate representation of company positions and achievements. /li liMonitors media coverage and sentiment, flagging emerging narratives before they require a crisis response. /li liEnsures consistent messaging across earned, owned, and shared channels, and aligns spokesperson strategy and media plans with global priorities. /li /ul h3Corporate Reputation Management and Corporate Public Affairs /h3 ul liOwns the country-level corporate reputation strategy for Italy ensuring consistency with the global corporate narrative and brand. /li liMonitors reputation indicators and stakeholder sentiment, giving leadership early warning of emerging risks and opportunities. /li liLeads local crisis and issues management, protecting and enhancing the company's reputation during sensitive events. /li liBuilds executive visibility and thought leadership within the local business, healthcare, and policy community, positioning leaders as trusted voices on oncology innovation. /li liIn partnership with the local Value, Market Access and Pricing team, pursues corporate Public Affairs activities, including engagement with government and stakeholder institutions in Italyon broader company issues. /li liMaps and monitors the evolving policy environment in Italy including government, institutions, and regulatory bodies, flagging risks and opportunities to the business. /li /ul h3Internal Communication /h3 ul liPartners with the GM, HR, and corporate functions to build a culture of transparency and pride in the company's oncology impact. /li liDesigns engagement strategies that build genuine commitment and translate strategy into clear priorities employees can act on. /li liAligns internal messaging with external priorities, cascading Italypolicy and access milestones through engaging channels. /li /ul h3Product and Disease Area Communications /h3 ul liLeads oncology communications strategy in Italy across disease awareness, launch, and lifecycle, including congress activity (ASCO, ESMO) that translates clinical data for HCP and media audiences, where and how permitted under local regulatory requirements. /li liCreates disease-awareness content for patients and caregivers, and partners with Medical Affairs to translate clinical data into HCP-facing communications. /li liEnsures communications comply with European promotional codes (EFPIA) and local regulations, maintaining clear promotional/non-promotional distinction and ethical standards. /li /ul h3Capability Building (Tech and AI) and Regional Alignment /h3 ul liBuilds team fluency in AI-enabled tools for audience insight, message drafting, and real-time measurement and sets clear standards for responsible, compliant use. /li liDevelops best-practice toolkits, guidance, and training that build local advocacy and policy capacity, including AI and digital literacy. /li liTreats digital and AI-enabled engagement as core, not optional, to contemporary corporate affairs communications. /li liFosters cross-country learning and alignment on both policy initiatives and emerging tools and practice. /li liPartners with Region and Global to align communications in Italy with the global narrative, feeding in policy insights, advocacy trends, and oncology milestones. /li /ul h3Required Skills, Experience and Education /h3 ul liDegree in Law, Communications, Political Science, Public Health, Life